Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer

Fulvestrant is recommended for patients with hormone receptor-positive (HR+) advanced breast cancer (ABC) who progress after aromatase inhibitor therapy. As most patients in this setting have already developed mechanisms of resistance to endocrine therapy, targeting biological pathways associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sammons, Sarah, Kornblum, Noah S., Blackwell, Kimberly L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407749/
https://www.ncbi.nlm.nih.gov/pubmed/30136059
http://dx.doi.org/10.1007/s11523-018-0587-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407749/
https://www.ncbi.nlm.nih.gov/pubmed/30136059
http://dx.doi.org/10.1007/s11523-018-0587-9

Ejemplares similares